# Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases

> **NCT02859415** · PHASE1,PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 3 (actual)

## Conditions studied

- Esophageal Neoplasms
- Lung Neoplasms
- Mesothelioma
- Thymus Neoplasms
- Neoplasms, Germ Cell and Embryonal

## Interventions

- **DRUG:** Mithramycin

## Key facts

- **NCT ID:** NCT02859415
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-08-08
- **Primary completion:** 2019-12-06
- **Final completion:** 2021-12-01
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Slow/Insufficient accrual
- **Last updated:** 2022-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02859415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02859415, "Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02859415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*